EGFR and non-small cell lung carcinoma: (74) also evaluated whether 18F-afatinib uptake could predict the response to afatinib therapy by evaluating 18F-afatinib PET/CT images of 12 patients with NSCLC, showing that 18F-afatinib PET/CT could serve as a method for precise quantification of EGFR mutation status in NSCLC patients who would benefit from afatinib therapy.